(Q41523505)

2 October 2017

1 reference

title

Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment (English)

1 reference

2 October 2017

1 reference

1 reference

Georgescu L

1

1 reference

2 October 2017

Quinn GC

series ordinal

2

1 reference

2 October 2017

Schwartzman S

series ordinal

3

1 reference

2 October 2017

Paget SA

series ordinal

4

1 reference

2 October 2017

language of work or name

1 reference

1 June 1997

1 reference

Seminars in Arthritis and Rheumatism

2 October 2017

1 reference

2 October 2017

26

1 reference

2 October 2017

794-804

1 reference

2 October 2017

6

1 reference

Factors influencing mortality in rheumatoid arthritis.

2 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Long-term experience with low dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

No Increase in Second Tumors after Cytotoxic Chemotherapy for Gestational Trophoblastic Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

1 reference

7 January 2021

Cancers complicating organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Is malignancy a major concern in rheumatoid arthritis patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Neoplasms of the immune system in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Increased Risk of Lymphoma in Sicca Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Cancer and rheumatoid arthritis: epidemiologic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Incidence of Cancer Among Patients With Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Evidence That the Malignant Lymphoma of Sjögren's Syndrome Is a Monoclonal B-Cell Neoplasm

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

CD5+ B cells in autoimmune disease and lymphoid malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Comparison of blood and synovial fluid lymphocyte subsets in rheumatoid arthritis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

T cell interactions in active rheumatoid arthritis: insights from the human autologous mixed lymphocyte reaction as a model of T cell activation cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Aberrant T-regulation in rheumatoid arthritis and IgA nephropathy affects CD5+ and CD5– B lymphocytes equally

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Impaired suppressor cell activity due to surface sulphydryl oxidation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Defective signal transduction via T-cell receptor-CD3 structure in T cells from rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Altered T lymphocyte signaling in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Restricted cytokine expression in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Mycobacterium tuberculosis antigen, interleukin 2 and interleukin 2 inhibitor in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Different defects of T cell regulation of Epstein-Barr virus-induced B cell activation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Variable Phenotypic Expression of an X-Linked Recessive Lymphoproliferative Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Detection of cytomegalovirus, Epstein-Barr virus and herpes virus-6 in patients with rheumatoid arthritis with or without Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Cytogenetic effects of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Human mitotic and meiotic chromosome damage following in vivo exposure to methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Sister chromatid exchange in patients treated with methotrexate for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Constitutive fragile sites and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Role of natural killer cells in the destruction of circulating tumor emboli

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Methyl-acetylenicputrescine (MAP), an inhibitor of polyamine biosynthesis, reduces the frequency and cytolytic activity of alloantigen-induced LyT 2.2 positive lymphocytes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Intracellular polyamine biosynthesis is required for interleukin 2 responsiveness during lymphocyte mitogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Antiproliferative effects of methotrexate on peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Effect of methotrexate on the immune response in children with acute lymphatic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Infections during low-dose methotrexate treatment in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Life-span carcinogenicity tests with 4-amino-N10-methylpteroylglutamic acid (methotrexate) in Swiss mice and Syrian golden hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980023-6

7 January 2021

10.1016/S0049-0172(97)80023-6

Identifiers

DOI

1 reference

2 October 2017

1 reference